Vanda Pharmaceuticals Up, Nike Gains, Biggest Winners of 2025
On this episode of Stock Movers:- Vanda Pharmaceuticals (VNDA) shares soar as much as 24% in premarket trading on Wednesday after the biopharmaceutical company said the US FDA has approved Nereus (tradipitant) for the prevention of vomiting induced by motion.- Nike (NKE) shares rose 1.6% in postmarket trading after CEO Elliott Hill reported the purchase of about $1 million in shares.- The S&P 500 Index is poised to end 2025 up more than 17% as the bull market continues for a third year driven by enthusiasm for artificial intelligence. The AI trade broadened out this year, as chip stocks again…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.